EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep

Ingo Fietze, Marie-Laure Boof iD, Katharina Lederer iD, Vincent Lemoine, Cedric Vaillant, Jean-Louis Pépin iD

SLEEP · 09.09.2026 · 49 (9)

DOI: 10.1093/sleep/zsag145 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift SLEEP, online erschienen am 22.05.2026. Verfasst von Ingo Fietze und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Sleep Medicine, Charite-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Pyrrolidines, Sleep, Sleep Apnea, Obstructive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives To evaluate the effect of daridorexant on nighttime respiratory function and sleep in adults with severe obstructive sleep apnea (OSA) without insomnia. Materials and Methods This randomized, double-blind, placebo-controlled, two-period, crossover trial was conducted at a single sleep center in 16 adults (≥18 years) with severe OSA without insomnia. In each period, daridorexant 50 mg or placebo was administered every evening for 5 days. Primary and secondary endpoints were the treatment differences (daridorexant–placebo) for apnea/hypopnea index (AHI) and oxygen saturation (SpO2) during total sleep time (TST), respectively, after last dosing. A mean increase in AHI ≥10 events/h and mean decrease in nocturnal SpO2 ≤–2% were the minimum changes considered to be clinically meaningful negative effects. Other endpoints included TST, latency to persistent sleep (LPS), and wake after sleep onset (WASO).

Results

Mean baseline AHI was 51.2 events/h (range 30.8, 82.2) and mean SpO2 during TST was 92.1% (range 88.5, 94.3). No clinically meaningful effect of daridorexant on AHI or SpO2 during TST was detected. Treatment differences were −3.7 events/h (one-sided 95% CI ≤ +4.2) and − 0.12 % (one-sided 95% CI ≥ −0.6), respectively. Compared with placebo, daridorexant increased TST by 32.5 min (90% CI: 6.9, 58.2), associated with shorter LPS (−10.3 min [90% CI: −20.6, −0.02]) and a trend towards reduced WASO (−15.2 min [−31.2, 0.9]). Four adverse events were reported (daridorexant n = 3; placebo n = 1), all of mild intensity and none related to respiratory function.

Conclusion

Short-term treatment with daridorexant does not impair sleep-disordered breathing and may improve sleep in patients with severe OSA. Clinical trial ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05458193, NCT05458193. Statement of Significance Obstructive sleep apnea (OSA) is highly prevalent and associated, in 30%-50% of cases, with insomnia-related symptoms, yet the safety of insomnia medications in OSA remains unclear. Daridorexant, a dual orexin receptor antagonist for the treatment of adults with insomnia disorder, previously showed no negative effect on sleep-disordered breathing in participants with mild/moderate OSA. This randomized, double-blind, placebo-controlled, crossover trial evaluates daridorexant 50 mg (maximum therapeutic dose) in participants with severe OSA without insomnia. Repeated dosing (5 nights) did not impair nighttime respiratory function, as assessed by apnea/hypopnea index and nocturnal oxygen saturation. Moreover, improvements in sleep characteristics were observed with daridorexant, extending evidence that daridorexant 50 mg is safe and well-tolerated and may improve sleep in adults with severe OSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolidinesSleepSleep Apnea, ObstructiveAdultFemaleHumansMaleMiddle AgedCross-Over StudiesDouble-Blind MethodOxygen SaturationPolysomnographySeverity of Illness IndexTreatment OutcomeImidazoles

Stichwörter der Autor:innen

daridorexantdual orexin receptor antagonistnighttime respirationsevere obstructive sleep apneasleep

Substanzen

daridorexantPyrrolidinesImidazoles

Autor:innen und Institutionen

  • Center of Sleep Medicine, Charite-Universitätsmedizin Berlin, Berlin, Germany.
  • Idorsia Pharmaceuticals Ltd, Allschwil, Basel-Landschaft, Switzerland.
  • Advanced Sleep Research GmbH, Berlin, Germany.
  • HP2 Laboratory, INSERM U1300, Grenoble Alpes University Hospital and EFCR Laboratory, Thorax and Vessels Division, Grenoble, France.

ORCID-Profile: Marie-Laure Boof, Katharina Lederer, Jean-Louis Pépin

Zitieren

APA

Fietze, I., Boof, M. L., Lederer, K., Lemoine, V., Vaillant, C., & Pépin, J. L. (2026). Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep. SLEEP, 49(9). https://doi.org/10.1093/sleep/zsag145

Vancouver

Fietze I, Boof ML, Lederer K, Lemoine V, Vaillant C, Pépin JL. Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep. SLEEP. 2026;49(9). doi:10.1093/sleep/zsag145

BibTeX
@article{Fietze2026,
  author = {Fietze, Ingo and Boof, Marie-Laure and Lederer, Katharina and Lemoine, Vincent and Vaillant, Cedric and Pépin, Jean-Louis},
  title = {Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep},
  journal = {SLEEP},
  year = {2026},
  volume = {49},
  number = {9},
  doi = {10.1093/sleep/zsag145}
}
Kostenlos starten →